Industry: Medical
Automated drug design

Client:

European Med-tech startup

Situation:

  • a vast range of molecules to examine during the screening process
  • the high cost of the screening process in terms of time and chemical resources
  • the uncertainty of the results of the screening process

Solution:

Deep Generative Models

Business Value:

  • reduced initial group of molecules for the screening process (by a factor of 10)
  • reduced cost of time and resources required
  • increased hit precision of the screening process
Automated Drug Design